THE SCIENTIFIC ADVISORY BOARD RECOMMENDS IFNα KINOID DEVELOPMENT FOR TYPE 1 DIABETES

Paris and Boston, January 25, 2017- Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the recommendation of its Scientific Advisory Board to extend the development of IFN Kinoid to a new indication, Type 1 Diabetes, with the objectives of obtaining preclinical proof of concept in 2017 and initiating clinical development for this program in the first half of 2018. IFN Kinoid is also currently in Phase IIb testing for treatment of Lupus and recently received U.S. FDA Fast Track designation in this indication.

Neovacs SA published this content on 25 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 January 2017 09:26:03 UTC.

Original documenthttp://neovacs.fr/neovacs-reports-first-positive-immunogenicity-results-for-ifna-kinoid-in-model-of-type-1-diabetes/

Public permalinkhttp://www.publicnow.com/view/45780029B187B7F588FB0A54167631EE388F0DA7